- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, HEOR, Combination therapy, Metastases: AFEQT: Colorectal Cancer Metastatic (clinicaltrials.gov) - Aug 22, 2012 P3, N=200, Recruiting, N=20 --> 45 Not yet recruiting --> Recruiting
- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
New P3 trial, HEOR, Combination therapy, Metastases: AFEQT: Colorectal Cancer Metastatic (clinicaltrials.gov) - Aug 20, 2012 P3, N=200, Recruiting,
- |||||||||| Enrollment open: FOLFIRINOX + RT for Pancreatic Cancer (clinicaltrials.gov) - Aug 16, 2012
P2, N=50, Recruiting, Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment change, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Aug 15, 2012 P1, N=20, Recruiting, Not yet recruiting --> Recruiting N=12 --> 20
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Metastases: Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients (clinicaltrials.gov) - Jul 15, 2012 P4, N=1500, Active, not recruiting, Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
|